In a filing, Design Therapeutics Inc revealed its Director William Arsani unloaded Company’s shares for reported $2.95 million on Aug 13 ’25. In the deal valued at $5.25 per share,562,627 shares were sold. As a result of this transaction, William Arsani now holds 1,000,000 shares worth roughly $6.05 million.
Then, Logos Opportunities Fund II LP bought 217,627 shares, generating $1,083,783 in total proceeds.
Before that, Logos Global Master Fund LP bought 345,000 shares. Design Therapeutics Inc shares valued at $1,718,100 were divested by the Director at a price of $4.98 per share.
Piper Sandler upgraded its Design Therapeutics Inc [DSGN] rating to an Overweight from a a Neutral in a research note published on May 07, 2024; the price target was increased to $12 from $6. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who decreased its forecast for the stock in mid November from “an Overweight” to “a Neutral”. Wedbush also remained covering DSGN and has decreased its forecast on August 15, 2023 with a “Neutral” recommendation from previously “an Outperform” rating. SVB Securities revised its rating on August 15, 2023. It rated DSGN as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of DSGN
On Friday, Design Therapeutics Inc [NASDAQ:DSGN] saw its stock fall -3.20% to $6.05. Over the last five days, the stock has gained 0.33%. Design Therapeutics Inc shares have risen nearly 4.85% since the year began. Nevertheless, the stocks have fallen -1.94% over the past one year.
How much short interest is there in Design Therapeutics Inc?
A steep rise in short interest was recorded in Design Therapeutics Inc stocks on 2025-08-29, growing by 23392.0 shares to a total of 3.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 3.49 million shares. There was a rise of 0.67%, which implies that there is a positive sentiment for the stock.
